IL258008A - Preventing, treating, and reducing (persistent) post-traumatic headache - Google Patents
Preventing, treating, and reducing (persistent) post-traumatic headacheInfo
- Publication number
- IL258008A IL258008A IL258008A IL25800818A IL258008A IL 258008 A IL258008 A IL 258008A IL 258008 A IL258008 A IL 258008A IL 25800818 A IL25800818 A IL 25800818A IL 258008 A IL258008 A IL 258008A
- Authority
- IL
- Israel
- Prior art keywords
- persistent
- treating
- post
- preventing
- reducing
- Prior art date
Links
- 206010036313 Post-traumatic headache Diseases 0.000 title 1
- 230000002085 persistent effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| PCT/IB2016/055720 WO2017051385A1 (en) | 2015-09-24 | 2016-09-23 | Preventing, treating, and reducing (persistent) post-traumatic headache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL258008A true IL258008A (en) | 2018-06-28 |
Family
ID=57121460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258008A IL258008A (en) | 2015-09-24 | 2018-03-11 | Preventing, treating, and reducing (persistent) post-traumatic headache |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (enExample) |
| EP (1) | EP3353202B1 (enExample) |
| JP (2) | JP2018532728A (enExample) |
| KR (2) | KR20180058777A (enExample) |
| CN (1) | CN108473560A (enExample) |
| AU (2) | AU2016325738A1 (enExample) |
| CA (1) | CA2999809A1 (enExample) |
| EA (1) | EA201890578A1 (enExample) |
| ES (1) | ES2846878T3 (enExample) |
| HK (1) | HK1258385A1 (enExample) |
| IL (1) | IL258008A (enExample) |
| MX (1) | MX2018003713A (enExample) |
| WO (1) | WO2017051385A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602700B (zh) | 2011-05-20 | 2021-12-17 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
| JP6374789B2 (ja) | 2011-05-20 | 2018-08-15 | アルダーバイオ・ホールディングズ・エルエルシー | 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| HK1232218A1 (zh) | 2014-02-05 | 2018-01-05 | Merck Sharp & Dohme Llc | Cgrp-活性化合物的片剂制剂 |
| FI3119431T3 (fi) | 2014-03-21 | 2024-03-20 | Teva Pharmaceuticals Int Gmbh | Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi |
| KR20190066607A (ko) | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| MX2021008267A (es) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. |
| AU2020259461A1 (en) * | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| BR102020007149A8 (pt) | 2020-04-06 | 2023-09-26 | H Lundbeck As | Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca |
| MX2022015230A (es) | 2020-06-03 | 2023-01-04 | Miotox Llc | Metodos y usos zonal y dirigido para el tratamiento de un trastorno de migra?a. |
| JP2023535744A (ja) | 2020-07-29 | 2023-08-21 | アラーガン ファーマシューティカルズ インターナショナル リミテッド | 片頭痛の治療 |
| US12350259B2 (en) | 2021-09-27 | 2025-07-08 | Allergan Pharmaceuticals International Limited | Methods of treating migraine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| EP3045182B1 (en) * | 2005-11-14 | 2018-03-07 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache |
| CN107602700B (zh) * | 2011-05-20 | 2021-12-17 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
| MX2014008456A (es) * | 2012-01-10 | 2014-11-25 | Noxxon Pharma Ag | Acidos nucleicos que enlazan especificamente a cgrp. |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3353202B1 (en) | 2020-11-04 |
| AU2016325738A1 (en) | 2018-04-12 |
| WO2017051385A1 (en) | 2017-03-30 |
| JP2020002172A (ja) | 2020-01-09 |
| US20200148761A1 (en) | 2020-05-14 |
| MX2018003713A (es) | 2018-08-15 |
| EA201890578A1 (ru) | 2018-12-28 |
| KR20200035163A (ko) | 2020-04-01 |
| CA2999809A1 (en) | 2017-03-30 |
| EP3353202A1 (en) | 2018-08-01 |
| US20220048986A1 (en) | 2022-02-17 |
| CN108473560A (zh) | 2018-08-31 |
| US20170088612A1 (en) | 2017-03-30 |
| JP2018532728A (ja) | 2018-11-08 |
| AU2019261726A1 (en) | 2019-11-28 |
| HK1258474A1 (en) | 2019-11-15 |
| HK1258385A1 (zh) | 2019-11-08 |
| KR20180058777A (ko) | 2018-06-01 |
| ES2846878T3 (es) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258008A (en) | Preventing, treating, and reducing (persistent) post-traumatic headache | |
| AU2022204866B2 (en) | Methods For Treating Or Preventing Migraine Headache | |
| IL291153A (en) | Methods for treating or preventing migraine headaches | |
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| LT3349758T (lt) | Arenavirusų šeimos virusinių infekcijų gydymo būdai | |
| GB2542244B (en) | Security substrates, security devices and methods of manufacturing thereof | |
| HK1254672A1 (zh) | 治疗痛觉过敏的方法 | |
| GB201512215D0 (en) | Agents,uses and methods | |
| IL271728A (en) | Materials, uses and treatment methods | |
| IL247938A0 (en) | Onconas for use in the treatment or prevention of viral infections | |
| IL291266A (en) | Preparations and methods for treating infections | |
| EP3302695A4 (en) | Method and devices for treating muscles | |
| ZA201907283B (en) | Compositions, devices and methods for treating autism | |
| EP3283529A4 (en) | Agents, systems and methods for treating cancer | |
| ZA201904328B (en) | Composition, application thereof and treatment method | |
| EP3080222A4 (en) | Method for treating wood, wood product and use field of the invention | |
| GB201513018D0 (en) | Process, dispersions and use | |
| HK40015277A (en) | Compositions, devices and methods for treating obsessive-compulsive disorder | |
| SG11201804140PA (en) | Acidic-gas treating agent and acidic-gas treating method | |
| HK1257038A1 (en) | Composition for treating and preventing viral infections | |
| GB201518375D0 (en) | Agents,uses and methods | |
| GB201512211D0 (en) | Agents, uses and methods | |
| SG10201911439RA (en) | Interlacing methods, computer-readable media, and interlacing devices | |
| GB201501474D0 (en) | Agent, product and use |